

# Gilbert J Burckart

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8141413/publications.pdf>

Version: 2024-02-01

79  
papers

3,359  
citations

236612

25  
h-index

143772

57  
g-index

80  
all docs

80  
docs citations

80  
times ranked

2800  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Pharmacokinetics of Tacrolimus. <i>Clinical Pharmacokinetics</i> , 1995, 29, 404-430.	1.6	671
2	Clinical Pharmacokinetics of Cyclosporin. <i>Clinical Pharmacokinetics</i> , 1986, 11, 107-132.	1.6	431
3	Pharmacogenomic Biomarker Information in Drug Labels Approved by the United States Food and Drug Administration: Prevalence of Related Drug Use. <i>Pharmacotherapy</i> , 2008, 28, 992-998.	1.2	272
4	Extrapolation of Adult Data and Other Data in Pediatric Drug-Development Programs. <i>Pediatrics</i> , 2011, 128, e1242-e1249.	1.0	259
5	Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms. <i>American Journal of Transplantation</i> , 2003, 3, 477-483.	2.6	239
6	Tacrolimus Dosing in Adult Lung Transplant Patients Is Related to Cytochrome P4503A5 Gene Polymorphism. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 135-140.	1.0	130
7	The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. <i>Human Immunology</i> , 2002, 63, 765-770.	1.2	98
8	Adolescent Dosing and Labeling Since the Food and Drug Administration Amendments Act of 2007. <i>JAMA Pediatrics</i> , 2013, 167, 926.	3.3	89
9	Disparate Distribution of 16 Candidate Single Nucleotide Polymorphisms Among Racial and Ethnic Groups of Pediatric Heart Transplant Patients. <i>Transplantation</i> , 2006, 82, 1774-1780.	0.5	67
10	Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 nonexpressors. <i>Transplant Immunology</i> , 2006, 15, 235-240.	0.6	63
11	Exposure Matching for Extrapolation of Efficacy in Pediatric Drug Development. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1326-1334.	1.0	58
12	Clinical Pharmacokinetics in Organ Transplant Patients. <i>Clinical Pharmacokinetics</i> , 1989, 16, 134-161.	1.6	57
13	Genetic Polymorphisms Impact the Risk of Acute Rejection in Pediatric Heart Transplantation: A Multi-Institutional Study. <i>Transplantation</i> , 2008, 85, 1632-1639.	0.5	56
14	A novel variant L263F in human inosine 5- $\alpha$ -monophosphate dehydrogenase 2 is associated with diminished enzyme activity. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 283-290.	0.7	47
15	The impact of P-glycoprotein and Mrp2 on mycophenolic acid levels in mice. <i>Transplant Immunology</i> , 2008, 19, 192-196.	0.6	38
16	Glomerular Filtration Rate Estimation Formulas for Pediatric and Neonatal Use. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2018, 23, 424-431.	0.3	36
17	Pharmacogenetics in Transplant Patients. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 23-30.	1.0	34
18	Physiologically Based Pharmacokinetic Models to Predict Maternal Pharmacokinetics and Fetal Exposure to Emtricitabine and Acyclovir. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 240-255.	1.0	34

#	ARTICLE	IF	CITATIONS
19	A Comparison of Pediatric and Adult Safety Studies for Antipsychotic and Antidepressant Drugs Submitted to the United States Food and Drug Administration. <i>Journal of Pediatrics</i> , 2019, 208, 236-242.e3.	0.9	32
20	Qualification of Biomarkers for Drug Development in Organ Transplantation. <i>American Journal of Transplantation</i> , 2008, 8, 267-270.	2.6	30
21	Translational Biomarkers: from Preclinical to Clinical a Report of 2009 AAPS/ACCP Biomarker Workshop. <i>AAPS Journal</i> , 2011, 13, 274-283.	2.2	29
22	Pediatric Drug Development: Outlook for Science-Based Innovation. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 376-378.	2.3	27
23	Neonatal Safety Information Reported to the FDA During Drug Development Studies. <i>Therapeutic Innovation and Regulatory Science</i> , 2018, 52, 100-108.	0.8	27
24	Renal Clearance in Newborns and Infants: Predictive Performance of Population-Based Modeling for Drug Development. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1462-1470.	2.3	27
25	Pediatric Drug-Drug Interaction Studies: Barriers and Opportunities. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1067-1070.	2.3	27
26	Monoclonal Antibodies and Fc-Fusion Proteins for Pediatric Use: Dosing, Immunogenicity, and Modeling and Simulation in Data Submitted to the US Food and Drug Administration. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1130-1143.	1.0	25
27	Identification of Factors Affecting Tacrolimus Level and 5-Year Clinical Outcome in Kidney Transplant Patients. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012, 111, 217-223.	1.2	23
28	Incorporating Ontogeny in Physiologically Based Pharmacokinetic Modeling to Improve Pediatric Drug Development: What We Know About Developmental Changes in Membrane Transporters. <i>Journal of Clinical Pharmacology</i> , 2019, 59, S56-S69.	1.0	23
29	Understanding the Genetic Basis for Adverse Drug Effects: The Calcineurin Inhibitors. <i>Pharmacotherapy</i> , 2010, 30, 195-209.	1.2	22
30	Obesity and Pediatric Drug Development. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 650-661.	1.0	20
31	Approaches to Dose Finding in Neonates, Illustrating the Variability between Neonatal Drug Development Programs. <i>Pharmaceutics</i> , 2020, 12, 685.	2.0	20
32	Update on the clinical pharmacogenomics of organ transplantation. <i>Pharmacogenomics</i> , 2010, 11, 227-236.	0.6	19
33	Primary Endpoints in Pediatric Efficacy Trials Submitted to the US FDA. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 885-890.	1.0	19
34	The Revolution in Pediatric Drug Development and Drug Use: Therapeutic Orphans No More. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2020, 25, 565-573.	0.3	19
35	Roadmap to 2030 for Drug Evaluation in Older Adults. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 210-223.	2.3	19
36	Predicting neonatal pharmacokinetics from prior data using population pharmacokinetic modeling. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1175-1183.	1.0	16

#	ARTICLE	IF	CITATIONS
37	Physiologically Based Pharmacokinetic Prediction of Linezolid and Emtricitabine in Neonates and Infants. <i>Clinical Pharmacokinetics</i> , 2017, 56, 383-394.	1.6	16
38	Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1433-1450.	1.6	16
39	Combined Pediatric and Adult Trials Submitted to the US Food and Drug Administration 2012â€“2018. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1018-1025.	2.3	15
40	Dosage Considerations for Canakinumab in Children With Periodic Fever Syndromes. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 557-567.	2.3	14
41	Exposureâ€“Response Assessment in Pediatric Drug Development Studies Submitted to the US Food and Drug Administration. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 90-98.	2.3	14
42	Physiologically Based Pharmacokinetic Modeling Framework to Predict Neonatal Pharmacokinetics of Transplacentally Acquired Emtricitabine, Dolutegravir, and Raltegravir. <i>Clinical Pharmacokinetics</i> , 2021, 60, 795-809.	1.6	14
43	Rectal thiopental versus an intramuscular cocktail for sedating children before computerized tomography. <i>American Journal of Health-System Pharmacy</i> , 1980, 37, 222-224.	0.5	11
44	Pharmacogenomics: The Key to Improved Drug Therapy in Transplant Patients. <i>Clinics in Laboratory Medicine</i> , 2008, 28, 411-422.	0.7	11
45	Pediatric Renal Ontogeny and Applications in Drug Development. <i>Journal of Clinical Pharmacology</i> , 2019, 59, S9-S20.	1.0	11
46	Adverse Event Detection and Labeling in Pediatric Drug Development: Antiretroviral Drugs. <i>Therapeutic Innovation and Regulatory Science</i> , 2015, 49, 302-309.	0.8	10
47	Ontogeny equations with probability distributions for anthropomorphic measurements in preterm and term neonates and infants for use in a PBPK model. <i>Computational Toxicology</i> , 2019, 11, 101-117.	1.8	9
48	Regulatory Considerations for the Mother, Fetus and Neonate in Fetal Pharmacology Modeling. <i>Frontiers in Pediatrics</i> , 2021, 9, 698611.	0.9	8
49	Enrichment Strategies in Pediatric Drug Development: An Analysis of Trials Submitted to the US Food and Drug Administration. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 983-988.	2.3	7
50	Mechanistic Modeling of Placental Drug Transfer in Humans: How Do Differences in Maternal/Fetal Fraction of Unbound Drug and Placental Influx/Efflux Transfer Rates Affect Fetal Pharmacokinetics?. <i>Frontiers in Pediatrics</i> , 2021, 9, 723006.	0.9	7
51	International Coherence of Pediatric Drug Labeling for Drug Safety: Comparison of Approved Labels in Korea and the United States. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 530-540.	2.3	6
52	Dosing Recommendations for Pediatric Patients With Renal Impairment. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1551-1560.	1.0	6
53	Ethical Considerations for Pediatric Placebo-Controlled Trials: FDA Outcomes and Perspectives. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 282-303.	0.8	6
54	Methods Used for Pediatric Dose Selection in Drug Development Programs Submitted to the US FDA 2012â€“2020. <i>Journal of Clinical Pharmacology</i> , 2021, 61, S28-S35.	1.0	6

#	ARTICLE	IF	CITATIONS
55	Drug development for pediatric neurogenic bladder dysfunction: Dosing, endpoints, and study design. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 1239-1246.	1.0	5
56	Bridging Adult Experience to Pediatrics in Oncology Drug Development. <i>Journal of Clinical Pharmacology</i> , 2017, 57, S129-S135.	1.0	5
57	Pediatric Development of Molecularly Targeted Oncology Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 384-389.	2.3	5
58	Surrogate Endpoints in Pediatric Studies Submitted to the US FDA. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 555-557.	2.3	5
59	Pediatric Ontogeny: Moving From Translational Science to Drug Development. <i>Journal of Clinical Pharmacology</i> , 2019, 59, S7-S8.	1.0	4
60	Predicting the pharmacokinetics of piperacillin and tazobactam in preterm and term neonates using physiologically based pharmacokinetic modeling. <i>Computational Toxicology</i> , 2019, 12, 100104.	1.8	4
61	Looking beneath the surface of the CYP3A5 polymorphism. <i>Pediatric Transplantation</i> , 2007, 11, 239-240.	0.5	3
62	Methodological Issues in the Design of Paediatric Pharmacokinetic Studies. <i>Pharmaceutical Medicine</i> , 2012, 26, 13-22.	1.0	3
63	The RACE to Develop New Targeted Therapies for Children With CNS Tumors. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 434-436.	2.3	3
64	Scientific and Regulatory Considerations for an Ontogeny Knowledge Base for Pediatric Clinical Pharmacology. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 707-709.	2.3	3
65	Extrapolation of Adult Efficacy to Pediatric Patients With Chemotherapy-Induced Nausea and Vomiting. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 775-784.	1.0	3
66	Drug Safety in Labeling for Pediatric Drug Development and Dose Selection in Submissions to the US Food and Drug Administration. <i>Journal of Clinical Pharmacology</i> , 2021, 61, S133-S140.	1.0	3
67	Applying the Noninferiority Paradigm to Assess Exposure-Response Similarity and Dose Between Pediatric and Adult Patients. <i>Journal of Clinical Pharmacology</i> , 2021, 61, S165-S174.	1.0	3
68	Progress in Drug Development- Pediatric Dose Selection: Workshop Summary. <i>Journal of Clinical Pharmacology</i> , 2021, 61, S13-S21.	1.0	3
69	Inclusion of Infants and Neonates in Pediatric Orphan Product Approvals. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 997-1003.	2.3	3
70	Progress in the Direct Application of Pharmacogenomics to Patient Care: Sustaining innovation. <i>Biomolecules and Therapeutics</i> , 2007, 15, 1-6.	1.1	3
71	Ciclosporin aerosol in lung transplantation. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 981-986.	1.9	2
72	Bone Mineral Density to Assess Pediatric Bone Health in Drug Development. <i>Therapeutic Innovation and Regulatory Science</i> , 2017, 51, 756-760.	0.8	2

#	ARTICLE	IF	CITATIONS
73	Neonatal and Pediatric Dose Selection: Quo Vadis?. Journal of Clinical Pharmacology, 2021, 61, S7-S8.	1.0	2
74	Pediatric Drug Development Studies for Familial Hypercholesterolemia Submitted to the US Food and Drug Administration Between 2007 and 2020. Journal of Clinical Pharmacology, 2022, 62, 397-408.	1.0	2
75	Pediatric and Adult Placebo Response Rates in Placebo-Controlled Clinical Trials Submitted to the US FDA 2012-2020. Journal of Clinical Pharmacology, 2022, , .	1.0	2
76	Evaluation of Physiologically Based Pharmacokinetic Models to Predict the Absorption of BCS Class I Drugs in Different Pediatric Age Groups. Journal of Clinical Pharmacology, 2021, 61, S94-S107.	1.0	1
77	Applications of Pharmacogenomics to Pediatric Drug Development. , 0, , 316-331.		0
78	Pediatric Drug Development and the Regulatory Changes That Are Creating the Science of Pediatric Dosing. , 2016, , 1-12.		0
79	Pediatric clinical pharmacology and therapeutics. , 2022, , 455-477.		0